Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / TF



This biomarker is also known as:
  • TRF,
  • PRO1557,
  • transferrin,
  • PRO2086,

View in BioMuta


TF, or transferrin, a glycoprotein with an approximate molecular weight of 76.5 kDa, is thought to have been created as a result of an ancient gene duplication event that led to generation of homologous C and N-terminal domains each of which binds one ion of ferric iron. The function of this protein is to transport iron from the intestine, reticuloendothelial system, and liver parenchymal cells to all proliferating cells in the body. This protein may also have a physiologic role as granulocyte/pollen-binding protein (GPBP) involved in the removal of certain organic matter and allergens from serum.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Three
QA State: Curated


In laboratory testing, transferrin, in a panel (including apolipoprotein A-1, transthyretin, and CA125) has been shown to be a highly sensitive (96%) predictor of early stage ovarian cancer and endometrial cancer.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. TF alone was not a strong predictor.



Phase: One
QA State: Under Review


No additional prostate data available.

Performance Comment

19 common probe sets (15 unique genes) were used to develop a PAM-based classifier, which had an average accuracy of 87% when it was tested on 47 independent tumor-adjacent stroma samples. The 15 genes represented in the classifier are: GADD45B, CDKN1A, NLRP1, ERBB3, FMO5, KIAA0746///SERINC2, AMFR, DPP4, PGC, YWHAE, EHF, TF, TNFSF10, EIF5A, TGM4. This is the first general tumor microenvironment-based prognostic classifier. Tumor-adjacent prostate cancer stroma contains numerous changes in gene expression at the time of diagnosis that correlate with the chance of relapse following prostatectomy. These results indicate that the prostate cancer microenvironment exhibits reproducible changes useful for predicting outcomes for patients.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.